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Saccharomyces cerevisiaeLysine deacetylases (KDACs) inhibitors may have therapeutic value in anti-malarial combination
therapies with artemisinin. To evaluate connections between KDACs and artemisinin, Saccharomy-
ces cerevisiae deletion mutants in KDAC genes were assayed. Deletion of RPD3, but not other KDAC
genes, resulted in strong sensitivity to artemisinin, which was also observed in sit4D mutants with
impaired endoplasmic reticulum (ER) to Golgi protein trafﬁcking. Decreased accumulation of the
transporters Pdr5p, Fur4p, and Tat2p was observed in rpd3D and sit4D cells. The unfolded protein
response is induced in rpd3D cells consistent with retention of proteins in the ER. Disruption of pro-
tein trafﬁcking appears to sensitize cells to artemisinin and targeting these pathways may be useful
as part of artemisinin based anti-malarial therapy.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Malaria, caused by infection with Plasmodium species, is preva-
lent in tropical and subtropical regions, resulting in more than
three billion people being at risk of infection [1,2]. The latest report
from the World Health Organization estimates that there are over
200 million cases of malaria worldwide, with an estimated 627,000
deaths from the disease in 2012 [3]. However, mortality rates for
malaria have been lowered over the last decade in part through
treatment with artemisinin-based combination therapies [4–6].
Artemisinin was identiﬁed in Artemisia annua as part of screen
for plant extracts that contained anti-malarial properties [7–9]
and has become a widely used anti-malarial drug [4,10,11].
Although the exact molecular basis of artemisinin-mediated toxic-
ity remains under debate [12,13], artemisinin and its derivativesare the most potent anti-malarial drugs thus far identiﬁed [14].
Two biochemical modes of action of artemisinins have been
reported and involve either speciﬁc inhibition of intracellular cal-
cium channels or free radical production in mitochondria following
artemisinin exposure [15–20].
Currently, several different artemisinin-based combination
therapies are utilized in malaria endemic countries to enhance
the effectiveness of treatment and to minimize the development
of resistance [21–23]. Unfortunately, utilizing these strategies has
not prevented the appearance of artemisinin resistant Plasmodium
isolates that have the potential to compromise the use of artemis-
inin-based therapies [24–26]. The spread of artemisinin resistant
parasites has the potential to have catastrophic consequences, sim-
ilar to that observed with the advent of chloroquine-resistant and
sulfadoxine-pyrimethamine-resistant parasites [27]. The increas-
ing problem of artemisinin resistance in Plasmodium species
emphasizes the need to develop alternative strategies to enhance
effectiveness of artemisinin.
A potential drug target that may have utility in artemisinin-
based anti-malarial therapies is the lysine deacetylases (KDACs)
class of enzymes. Inhibitors of KDAC enzymes are active against
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KDAC inhibitors and the mechanisms through which they exhibit
anti-malarial activities are not entirely clear [28–33]. KDAC
enzymes were originally identiﬁed for their role in the post-trans-
lational modiﬁcation of lysines on histone proteins and the
regulation of transcription through altering of chromatin structure
[34–37]. In addition, the regulation of acetylation of non-histone
proteins by KDACs has also been shown to be involved in the con-
trol of other cellular pathways [32,38–42]. The P. falciparum gen-
ome encodes ﬁve KDAC enzymes [43,44], although the speciﬁc
KDACs that are targets for anti-malarial therapy have not been
determined.
The yeast Saccharomyces cerevisiae is a powerful model system
for identifying genes and biochemical pathways involved in the
action or resistance of drugs [45–47]. Even though S. cerevisiae
lacks a close orthologue of PfATP6 [15,48], a proposed target of
artemisinin, and exhibits greater artemisinin resistance than P. fal-
ciparum [16], the yeast model has proven useful in the investiga-
tion of artemisinin action [16,17,49]. In this study, we utilized S.
cerevisiae to investigate the possible connection between KDAC
activity and artemisinin resistance. We report here that deletion
of the KDAC RPD3 results in sensitivity to artemisinin due in part
to defects in protein trafﬁcking.Fig. 1. Deletion of RPD3 causes sensitivity to artemisinin. Artemisinin sensitivity in
deletion strains lacking individual KDAC genes (rpd3D, hda1D, hos1D, hos2D, hos3D,
sir2D, hst1D, hst2D, hst3D, hst4D) was assayed. Yeast growth was monitored by
spotting 105, 104, or 103 cells on SCG medium supplemented with the indicated
artemisinin concentrations followed by incubation at 30 C for 4 days.2. Materials and methods
2.1. Yeast strains and growth conditions
Yeast strains used in this study were derived from BY4742 (Mat
a, leu2D0, lys2D0, ura3D0, his3D1) [50] and single deletion strains
were obtained from Open Biosystems. Double deletion strains
were generated using plasmids pWC006, pWC008, and pWC020
resulting in strains WC061 (msn2D::URA3, msn4D::kanMX4),
WC081 (pdr1D::HIS3, pdr3D::kanMX4), WC131 (pdr5D::kanMX4,
snq2D::HIS3) and WC201 (rpd3D::HIS3, end3D::kanMX4). Gene
deletions were veriﬁed by in vivo PCR using ﬂanking primers [51].
Yeast transformations were performed using the lithium ace-
tate procedure [52]. Cells were propagated at 30 C either in
enriched yeast extract, peptone based medium supplemented with
2% glucose (YPD), synthetic complete medium with 2% glucose
(SC), 2% glycerol (SCG) or 2% glycerol and 2% ethanol (SCGE) [53].
2.2. Plasmids
Deletion plasmids pWC006 (MSN2 disruption), pWC008 (PDR1
disruption), and pWC020 (RPD3 disruption) were generated using
standard procedures and utilized plasmids pRS306 (URA3) or
pRS403 (HIS3) [54]. Plasmid pWC018 expresses a PDR5-GFP fusion
driven by the PGK1 promoter. Details of construction can be found
in Supplemental material. Plasmids pLJ458 (FUR4-GFP), and pLJ459
(TAT2-GFP) have been described previously and utilize the PGK1
promoter [55].
2.3. Immunoblots
Cultures were grown in SCGE medium to a ﬁnal OD 600 nm of
approximately 1. Extracts were generated using NaOH lysis with
TCA precipitation as previously described [56]. Proteins were sep-
arated using SDS–PAGE with 10% Bis-Tris gels (Life Technologies)
and immunoblots were probed with anti-GFP (Santa Cruz Biotech-
nology) or anti-Pgk1 (Abcam) antibody at a 1:5000 dilution. Visu-
alization of immunoblots utilized a HRP conjugated secondary
antibody and ECL detection (Merck Ltd.) with a G:Box Chemi
XL1.4 chemiluminescence imaging system (Syngene). As a loading
control a duplicate gel was stained with Coomassie blue.2.4. Fluorescence Imaging
GFP ﬂuorescence was visualized in live cells [55,57] and viewed
directly at a magniﬁcation of 60 with an Olympus FV10i-DOC
confocal laser scanning microscope, equipped with universal plan
super apochromat phase contrast oil-immersion objective (Olym-
pus Bioimaging Center, Mahidol University).
2.5. b-Galactosidase assays
Transformants containing the UPRE-lacZ reporter (pPW344)
[58] were grown in SC or SCGE medium lacking uracil. b-Galacto-
sidase activities were assayed using ONPG as a substrate and
results from two independent transformants, assayed at least in
duplicate, are reported in Miller units [59].
3. Results
3.1. Deletion of RPD3 sensitizes yeast to artemisinin
Growth on glycerol containing medium was chosen for screen-
ing KDAC mutants to force respiration, to better mimic conditions
in other cell types such as Plasmodium parasites and to enhance
artemisinin toxicity [16,49]. The majority of the S. cerevisiae
KDACs genes are not required for resistance to artemisinin. Only
loss of RPD3 and SIR2 resulted in increased artemisinin sensitivity
(Fig. 1A). Growth inhibition from artemisinin exposure in the
sir2D strain was moderate when compared to the strong sensitiv-
ity observed in the rpd3D strain. Rpd3p exists in two major com-
plexes, Rpd3L and Rpd3S [60–62] and deletion of Rpd3L complex
subunits resulted in slightly greater artemisinin sensitivity than
loss of a Rpd3S subunit (Fig. S1). However, a deﬁnitive determi-
nation of the Rpd3 complex involved in artemisinin resistance
will require further analysis as deletion of subunits in neither
complex resulted in the artemisinin sensitivity observed in rpd3D
cells.
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Rpd3p has a known role in stress response [63] and has been
implicated in transcriptional control of both the environmental
stress response (ESR), mediated by Msn2p and Msn4p [62,64] as
well as the pleiotropic drug response, regulated by Pdr1p/Pdr3p
[65]. Loss of the MSN2 and MSN4 genes caused only a slight
increase in artemisinin sensitivity while deletion of PDR1 and
PDR3 resulted in more pronounced sensitivity to artemisinin
(Fig. 2A). However, the pdr1D pdr3D cells or strains deleted for
plasma membrane drug efﬂux transporters (Fig. S2) did not exhibit
the high degree of sensitivity to artemisinin observed in the rpd3D
strain. This suggests that additional factors or other modes of reg-
ulation are involved in loss of tolerance to artemisinin in cells lack-
ing Rpd3p.
3.3. Defects in speciﬁc protein trafﬁcking steps result in artemisinin
sensitivity
Altered trafﬁcking of several proteins has been previously dem-
onstrated in rpd3D cells [41,66] and defects in speciﬁc protein traf-
ﬁcking steps in rpd3D cells could contribute to artemisinin
sensitivity. Testing deletion strains containing defects in protein
trafﬁcking end3D (endocytosis), vps45D (Golgi to endosome/pre-
vacuolar compartment), sit4D (ER to Golgi), vps27D (recycling of
Golgi proteins), vps28D (sorting into endosomes), vps38D (carboxy
peptidase Y sorting) and vps29D (endosome to Golgi) [67,68]
revealed that loss of Sit4p, involved in endoplasmic reticulum
(ER) to Golgi transport, resulted in sensitivity to artemisinin simi-
lar to that seen in rpd3D cells (Fig. 2B). The remaining deletionFig. 2. The PDR system and SIT4 are involved in resistance to artemisinin.
Artemisinin sensitivity of WT and rpd3D cells and (A) strains deleted for regulators
of the PDR, pdr1D pdr3D, ESR, msn2D msn4D, and (B) deletions strains for
components in protein trafﬁcking pathways (end3D, vps45D, sit4D, vps27D, vps28D,
vps38D, vps29D) were monitored for artemisinin sensitivity in SCG medium as
described in Fig. 1.strains tested exhibited WT or near WT levels of artemisinin resis-
tance, except for vps28D cells that displayed moderate sensitivity.
To determine whether the rpd3D and sit4D cells were generally
stress sensitive we examined resistance to hydrogen peroxide,
menadione, ethanol, b-mercaptoethanol, sodium chloride, and ele-
vated temperature (37 C), with the stress sensitive sod1D strain as
a control [69]. The rpd3D strain displayed a slight to moderate
increase in sensitivity to these stress insults relative to WT cells
(Fig. 3). The growth of sit4D cells was also reduced under these
conditions, especially in the presence of hydrogen peroxide, b-
mercaptoethanol, and sodium chloride. The sod1D strain is known
to display general stress sensitivity and was substantially more
sensitive to the stress conditions, except for artemisinin, where
sod1D cells were slightly resistant compared to the rpd3D strain
(Fig. 3). Artemisinin exposure appears to cause a more substantial
growth inhibition in rpd3D compared to other stress conditions.
Yeast sit4D mutants exhibit more general stress sensitivity than
rpd3D cells but are more resistant than the sod1D control under
most stress conditions, except hydrogen peroxide and sodium
chloride. It appears that the susceptibility of sit4D and rpd3D cells
to artemisinin is in part due to the general stress sensitivity of
these strains.
3.4. Reduced abundance of Pdr5p in rpd3D and sit4D cells
The pleiotropic drug resistance (PDR) transporter Pdr5p has
been implicated in artemisinin resistance [70] and we observedFig. 3. Stress resistance of rpd3D, sit4D, and other selected strains. WT, rpd3D,
pdr1D pdr3D and selected deletions strains with defects in protein trafﬁcking were
monitored for sensitivity to the indicated stress conditions in SCG medium as
described in Fig. 1. The sod1D strain (lacking the cytosolic superoxide dismutase)
was included as a control since this strain exhibits sensitivity to several stress
conditions.
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promoter, was capable of enhancing resistance in WT cells
(Fig. 4). In contrast, over-expression of PDR5 does not promote a
substantial increase in artemisinin resistance in rpd3D and sit4D
strains (Fig. 4). Artemisinin resistance was enhanced by over-
expression of Pdr5p-GFP in other mutants with defects in protein
trafﬁcking (Fig. 4), highlighting the speciﬁc effect from deletion
of RPD3 and SIT4.
The ﬂuorescence signal intensity of Pdr5p-GFP, in rpd3D and
sit4D strains is substantially reduced compared to WT cells
(Fig. 5A). Results with ﬂuorescence microscopy were conﬁrmed
using immunoblots (Fig. 5B) and demonstrate that Pdr5p-GFP
abundance is dramatically lower in rpd3D and sit4D cells. Pdr5p-
GFP abundance was also dramatically reduced in vps45D cells
(Fig. 5), containing impaired Golgi to endosome trafﬁcking [71].
In contrast to rpd3D cells, artemisinin resistance in the vps45D
strain could be enhanced by over-expression of Pdr5p-GFP
(Fig. 4). This discrepancy appears to be due to the localization pat-
tern of Pdr5p-GFP in vps45D cells, which is characterized by clear
plasma membrane ﬂuorescence and an absence of intracellular
Pdr5p-GFP signals (Fig. 5A). The levels of plasma membrane
Pdr5p-GFP in WT and vps45D strains appears similar, indicating
that trafﬁcking to the plasma membrane is not substantially
impaired in vps45D cells. Mutants with defects in other protein
trafﬁcking steps (vps27D, vps28D, and vps29D) are also distinct
from rpd3D and sit4D cells and exhibited ﬂuorescence intensityFig. 4. Over-expression of PDR5 does not enhance artemisinin resistance in rpd3D
and sit4D cells. The indicated strains containing a control vector () or expressing
Pdr5p-GFP (+) were assayed for artemisinin sensitivity in SCG medium lacking
uracil, as described in Fig. 1.at the plasma membrane similar to WT as well as containing intra-
cellular ﬂuorescence signals (Fig. 5A).
In pdr1D pdr3D cells, over-expression of Pdr5p-GFP enhanced
artemisinin resistance and Pdr5p-GFP localization was identical
to that observed in WT cells (Figs. 4 and 5A), ruling out a contribu-
tion of the PDR regulators on post-translational control of Pdr5p-
GFP. In addition, reduced Pdr5p-GFP levels in rpd3D and sit4D cells
are not due to altered expression from the PGK1 promoter. Endog-
enous Pgk1p abundance is similar to WT in rpd3D and sit4D strains
(Fig. 5C). Taken together, these results suggest that Rpd3p is
important for promoting accumulation of Pdr5p, with ER to Golgi
transport a possible candidate for the defective pathway in rpd3D
cells.
As our experiments were conducted in glycerol-based medium,
we examined if the effects from loss of RPD3 on Pdr5p-GFP protein
levels were dependent on the carbon source utilized. Consistent
with previous results [16], we observed that for WT cells the arte-
misinin concentration required for toxicity in glucose medium was
several orders of magnitude greater than that required to cause
growth inhibition in glycerol medium (Fig. 6A), suggesting that
the effects we observed are dependent on reactive oxygen species
derived from respiration [16]. In cells lacking RPD3 only minimal
artemisinin toxicity was observed in glucose medium, although
pdr5D cells displayed sensitivity in the presence of 1 mM artemis-
inin (Fig. 6A). Monitoring Pdr5p-GFP ﬂuorescence in glucose med-
ium revealed that Pdr5p-GFP is stabilized at the plasma membrane
in WT, rpd3D, and sit4D cells (Fig. 6). The more abundant levels of
Pdr5p and presumably other PDR transporters in glucose medium
would also be expected to enhance drug efﬂux, reducing artemisi-
nin toxicity under these conditions.
3.5. Accumulation of the transporters Fur4p and Tat2p is reduced in
rpd3D and sit4D cells
While the stability of Pdr5p is dramatically reduced in glycerol
medium, this effect does not appear to be sufﬁcient to produce the
high degree of artemisinin sensitivity seen in the rpd3D and sit4D
strains. Yeast pdr5D mutants are substantially more artemisinin
resistant than rpd3D and sit4D cells (Fig. 2), suggesting a more gen-
eral defect in protein trafﬁcking may be involved in increased arte-
misinin sensitivity in cells lacking Rpd3p. We examined whether
membrane transporters unrelated to the PDR system also had
altered stability in the rpd3D and sit4D strains by evaluating the
abundance of Fur4p-GFP and Tat2p-GFP, using microscopy and
immunoblots. In each case the level of these transporters was
markedly reduced in the rpd3D and sit4D strains compared to
WT cells (Fig. 7).
3.6. The unfolded protein response (UPR) is activated in rpd3D cells
The inability of rpd3D cells to correctly trafﬁc transporter pro-
teins may be a cause of stress in this strain. Accumulation of pro-
teins within the ER typically leads to activation of the unfolded
protein response (UPR) system that allows for removal of incor-
rectly folded or damaged proteins [72,73]. The activation of the
UPR was monitored using a UPRE-lacZ reporter plasmid and UPR
induction was observed in rpd3D cells both in glycerol and glucose
medium, compared to the WT control (Fig. 8).4. Discussion
To investigate the potential of various classes of KDACs to alter
resistance to artemisinin, we screened deletions strains for all
known KDAC genes in S. cerevisiae. Among the KDAC deletion
strains analyzed only rpd3D cells displayed a high degree of arte-
Fig. 5. Accumulation Pdr5p-GFP is reduced in cells lacking RPD3 and SIT4. (A) Fluorescence of Pdr5p-GFP, driven by the constitutive PGK1 promoter, was observed by
microscopy at 60magniﬁcation. Abundance of Pdr5p-GFP (B) or Pgk1p (C) was assayed in selected strains using immunoblots (top panel) and a Coomassie stained gels are
shown as loading controls (bottom panels). Transformants were cultured in SCGE medium lacking uracil to mid-log phase.
Fig. 6. Artemisinin sensitivity and altered trafﬁcking of Pdr5p-GFP in rpd3D and
sit4D strains is carbon source dependent. (A) Artemisinin sensitivity was monitored
as in Fig. 1 except using SC (glucose) medium. Plates were incubation at 30 C for
3 days. (B) Pdr5p-GFP ﬂuorescence was observed as described in Fig. 5 in SC
medium lacking uracil. Fig. 7. Fur4p and Tat2p accumulation is substantially reduced in rpd3D and sit4D
cells. (A) Fluorescence of Fur4p-GFP and Tat2p-GFP, driven by the constitutive PGK1
promoter, was observed as described in Fig. 4 in SCGE medium lacking uracil and
tryptophan. (B) Abundance of Fur4p-GFP and Tat2p-GFP was assayed using
immunoblots (top panels) with a Coomassie stained gel shown as a loading control
(bottom panels). Transformants were cultured in SCGE medium lacking uracil and
tryptophan to mid-log phase.
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general stress response and PDR pathways [62,64,65], however
loss of the regulators for these stress responses does not produce
the level of artemisinin sensitivity observed in the rpd3D strain.
Although of these two pathways loss of the PDR regulators results
in more sensitivity to artemisinin. We speculated that a non-tran-
scriptional effect on the PDR system could be the cause of altered
artemisinin resistance.
The Pdr5p drug efﬂux pump is involved in resistance to several
classes of compounds including anti-cancer drugs, fungicides,pesticides, herbicides [74,75] and is also important for artemisinin
resistance [70]. We observed that the constitutive expression of
Pdr5p substantially enhanced artemisinin resistance in WT cells
but not in the rpd3D strain, consistent with a non-transcriptional
effect of Rpd3p on Pdr5p. A possible mechanism to explain the
Fig. 8. The unfolded protein response is activated in rpd3D cells. b-Galactosidase
activity was measured in WT and rpd3D strains containing the UPRE-lacZ reporter
plasmid (pPW344) in (A) glycerol (SCGE) or (B) glucose (SC) containing medium.
Transformants were cultured in medium lacking uracil to mid-log phase. Results
are the averages of two trials, the error bars represent standard deviation.
Fig. 9. Model of proposed pathway leading to sensitization to artemisinin. (A)
Trafﬁcking of membrane proteins in WT cells. (B) Impaired ER to Golgi trafﬁcking of
proteins in rpd3D cells leads to ER stress and activation of the unfolded protein
response (UPR). Membrane proteins (Pdr5p, Fur4p, Tat2p, etc.) are degraded and fail
to reach the plasma membrane. Defects in ER to Golgi trafﬁcking appear to lead to
increased toxicity from artemisinin exposure, although the precise mechanism is
not known.
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and other transporters. Premature endocytosis of Pho84p has been
observed in the rpd3D strain [66]; however, blocking endocytosis
did not increase artemisinin resistance compared to rpd3D cells.
This suggests that other steps in protein trafﬁcking are also altered
due to deletion of RPD3. Of the mutants in protein trafﬁcking tested
only sit4D cells exhibited artemisinin sensitivity similar to therpd3D strain. However, sit4D and rpd3D cells displayed suscepti-
bility to several stress conditions indicating that enhanced sensi-
tivity to artemisinin may reﬂect a general weakness of these
strains. Sit4p has an established role in ER to Golgi trafﬁcking,
through its activity in the dephosphorylation of COPII coat sub-
units [76]. We observed that the relative abundance of Pdr5p-
GFP, Fur4p-GFP, and Tat2p-GFP in rpd3D and sit4D cells was sub-
stantially reduced compared to the WT strain. As these expression
plasmids utilized the constitutive PGK1 regulatory sequences, it is
unlikely that the reduced Pdr5p protein levels in the rpd3D and
sit4D cells strains are due to altered transcription. Instead we sug-
gest that degradation of these transporters is enhanced in rpd3D
and sit4D cells (Fig. 9).
In contrast to Pdr5p, which only displays aberrant trafﬁcking in
glycerol medium in rpd3D cells, mis-localization of the transport-
ers Hnm1p, Tat2p, and Itr1p was previously observed in glucose
medium [41]. This demonstrates that growth in glycerol is not
required for altered trafﬁcking of all transporters in the absence
of RPD3. In WT cells, Pdr5p is known to be less stable at the plasma
membrane in glycerol medium compared to when cells are grown
in glucose [77]. It is possible that the increased turnover of Pdr5p
in glycerol mediummay enhance the effects of the protein trafﬁck-
ing defects present in the rpd3D and sit4D strains.
Based on the reduced accumulation of Pdr5p, Fur4p, Tat2p in
both rpd3D and sit4D strains, it is possible that that ER to Golgi
trafﬁcking may be impaired in rpd3D. Retention of proteins in
the ER leads to induction of the unfolded protein response (UPR)
to clear the accumulated proteins, maintaining ER homeostasis
[72,73]. Consistent with aberrant accumulation of proteins in the
ER, expression of a UPR reporter was elevated in the rpd3D strain,
both in glucose and glycerol medium. ER to Golgi trafﬁcking is
required for degradation of mis-folded soluble proteins in the ER,
however this transport step is not essential for removal of mem-
brane proteins [78]. ER stress is rpd3D cells may in fact be due to
over-accumulation of soluble proteins in the ER lumen and not
necessarily loss of integral membrane proteins such as Pdr5p,
Fur4p, and Tat2p. It is possible that the combined effect of ER
stress, due to rpd3D mutations, with toxicity from artemisinin
exposure may overwhelm the capacity of the cellular stress
responses, leading to cell death.
Protein trafﬁcking and secretion have been proposed as a vul-
nerable pathway that could be targeted in the treatment of malar-
ial disease [79–81]. Drugs that interfere with the transport of
Plasmodium proteins through the secretory pathway can reduce
parasite proliferation [79,80,82] and may also sensitize them to
the effects of other drugs. Our analysis of rpd3D cells suggests that
combination therapy using artemisinin in conjunction with drugs
that disrupt protein trafﬁcking may be a possible strategy to
enhance the effectiveness of artemisinin based anti-malarial
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